quinazolines has been researched along with Dermatitis, Atopic in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Du, W; Huang, F; Li, M; Lin, Y; Qu, L; Rao, G; Sun, Y; Tong, X; Zhang, Y; Zhu, D | 1 |
| Kim, D; Park, Y; Srigouri, H | 1 |
| Ahluwalia, J; Borok, J; Eichenfield, LF; Udkoff, J; Waldman, A | 1 |
| Beck, L; Borok, J; Eichenfield, LF; Simpson, E; Tom, W; Udkoff, J | 1 |
| Furue, M; Kadono, T; Nakahara, T; Tsuji, G | 1 |
| Furue, M; Hagihara, A; Hojo, S; Kitahara, Y; Nomoto, M; Onozuka, D | 1 |
| Bissonnette, R; Boguniewicz, M; Guttman-Yassky, E; Hanifin, JM; Kilty, I; Purohit, V; Tallman, AM; Wollenberg, A; Zielinski, MA | 1 |
| Asano, O; Hishinuma, I; Inoue, C; Ishii, N; Kusano, K; Miyazaki, K; Shirato, M; Takase, Y; Wakita, H; Yamamoto, E | 1 |
| Han, NR; Jeong, HJ; Kim, HM; Moon, PD | 1 |
| Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z | 1 |
| Andoh, T; Kuraishi, Y; Yoshida, T | 1 |
| Akama, H; Furue, M; Hayashi, N; Hojo, S; Kitahara, Y; Nakagawa, H | 1 |
| Ishii, N; Shirato, M; Wakita, H | 1 |
| Akama, H; Hojo, S; Nomoto, M; Ohba, F | 1 |
| Furue, M; Hayashi, N; Hojo, S; Kitahara, Y; Nemoto, O; Nomoto, M; Shima, S | 1 |
| Akama, H; Hojo, S; Imayama, S; Matsuguma, K; Matsuki, S; Nomoto, M; Ohba, F | 1 |
| Guo, YN; Tong, M; Zhang, GY | 1 |
| Bradley, M; Homey, B; Nordenskjöld, M; Pivarcsi, A; Sääf, A; Tengvall-Linder, M; Wahlgren, CF; Winge, MC | 1 |
| Baudin, M; Braun-Falco, O; Brechtel, B; Christophers, E; Czarnetzki, BM; Dupuy, P; Reckers-Czaschka, R; Schöpf, E | 1 |
4 review(s) available for quinazolines and Dermatitis, Atopic
| Article | Year |
|---|---|
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.
Topics: Anisoles; Anti-Inflammatory Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic Nucleotide Phosphodiesterases, Type 4; Dermatitis, Atopic; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines | 2017 |
Atopic dermatitis: emerging therapies.
Topics: Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antipruritics; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Dermatologic Agents; Emollients; Humans; Infant; Infant Formula; Interleukin-13; Interleukin-4; Nitriles; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Probiotics; Quinazolines | 2017 |
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Topics: Administration, Topical; Adult; Animals; Antipruritics; Child; Dermatitis, Atopic; Humans; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines | 2017 |
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
Topics: Acetamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Drug Approval; Humans; Immune System; Inflammation; Phosphodiesterase Inhibitors; Phthalic Acids; Pyridines; Quinazolines; Risk; Skin; Thalidomide | 2019 |
6 trial(s) available for quinazolines and Dermatitis, Atopic
| Article | Year |
|---|---|
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Tissue Distribution; Treatment Outcome; Young Adult | 2019 |
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Topics: Administration, Topical; Adult; Asian People; Dermatitis, Atopic; Female; Humans; Japan; Male; Middle Aged; Ointments; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Time Factors; Treatment Outcome; Young Adult | 2014 |
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
Topics: Administration, Topical; Adult; Aged; Dermatitis, Atopic; Double-Blind Method; Healthy Volunteers; Humans; Male; Middle Aged; Ointments; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Young Adult | 2016 |
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Topics: Administration, Topical; Adolescent; Antipruritics; Child; Child, Preschool; Dermatitis, Atopic; Female; Humans; Japan; Male; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Treatment Outcome | 2016 |
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Topics: Administration, Cutaneous; Adult; Dermatitis, Atopic; Dose-Response Relationship, Drug; Humans; Male; Ointments; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Treatment Outcome | 2016 |
Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema.
Topics: Administration, Cutaneous; Adult; Cell Degranulation; Dermatitis, Atopic; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Mast Cells; Quinazolines; Treatment Outcome | 1993 |
9 other study(ies) available for quinazolines and Dermatitis, Atopic
| Article | Year |
|---|---|
Vasicine alleviates 2,4-dinitrochlorobenzene-induced atopic dermatitis and passive cutaneous anaphylaxis in BALB/c mice.
Topics: Alkaloids; Animals; Anti-Allergic Agents; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Immunoglobulin E; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Quinazolines; Skin; Skin Diseases | 2022 |
Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling.
Topics: Dermatitis, Atopic; Humans; Interleukin-13; Interleukin-4; Keratinocytes; Quinazolines | 2023 |
Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Cell Adhesion Molecules; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Lymphocytes; Male; Metabolic Clearance Rate; Mice; Mice, Inbred Strains; Monocytes; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Quinazolines; Rats; Rats, Sprague-Dawley; Skin; Tissue Distribution | 2013 |
Tryptanthrin ameliorates atopic dermatitis through down-regulation of TSLP.
Topics: Animals; Calcimycin; Calcium Ionophores; Cell Line; Cytokines; Dermatitis, Atopic; Dinitrofluorobenzene; Down-Regulation; Humans; Male; Mast Cells; Mice; Quinazolines; Skin; Spleen; Tetradecanoylphorbol Acetate; Thymic Stromal Lymphopoietin | 2014 |
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells | 2014 |
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Topics: Animals; Antipruritics; Cyclic AMP; Dermatitis, Atopic; Disease Models, Animal; Inflammation; Male; Mice; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines; Signal Transduction; Skin | 2014 |
Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Topics: Animals; Dermatitis, Atopic; Disease Models, Animal; Humans; Mice; Nerve Growth Factor; Phosphodiesterase 4 Inhibitors; Phthalic Acids; Pruritus; Quinazolines | 2014 |
[Effect and mechanisms of rutaecarpine on treating atopic dermatitis in mice].
Topics: Animals; Dermatitis, Atopic; Female; Immunoglobulin E; Indole Alkaloids; Interferon-gamma; Interleukin-4; Male; Mice; Quinazolines | 2011 |
Characterization of EGFR and ErbB2 expression in atopic dermatitis patients.
Topics: Adolescent; Adult; Cell Differentiation; Cell Line; Chemokine CCL26; Chemokines, CC; Dermatitis, Atopic; ErbB Receptors; Female; Humans; Inflammation Mediators; Interleukin-4; Keratinocytes; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Skin; Th2 Cells; Transcription, Genetic; Young Adult | 2012 |